Cargando…
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising tar...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161160/ https://www.ncbi.nlm.nih.gov/pubmed/30149610 http://dx.doi.org/10.3390/vaccines6030056 |
_version_ | 1783358929768546304 |
---|---|
author | Tuyaerts, Sandra Amant, Frédéric |
author_facet | Tuyaerts, Sandra Amant, Frédéric |
author_sort | Tuyaerts, Sandra |
collection | PubMed |
description | Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease. |
format | Online Article Text |
id | pubmed-6161160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61611602018-10-01 Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy Tuyaerts, Sandra Amant, Frédéric Vaccines (Basel) Review Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease. MDPI 2018-08-25 /pmc/articles/PMC6161160/ /pubmed/30149610 http://dx.doi.org/10.3390/vaccines6030056 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tuyaerts, Sandra Amant, Frédéric Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy |
title | Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy |
title_full | Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy |
title_fullStr | Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy |
title_full_unstemmed | Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy |
title_short | Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy |
title_sort | endometrial stromal sarcomas: a revision of their potential as targets for immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161160/ https://www.ncbi.nlm.nih.gov/pubmed/30149610 http://dx.doi.org/10.3390/vaccines6030056 |
work_keys_str_mv | AT tuyaertssandra endometrialstromalsarcomasarevisionoftheirpotentialastargetsforimmunotherapy AT amantfrederic endometrialstromalsarcomasarevisionoftheirpotentialastargetsforimmunotherapy |